Calliditas Therapeutics announced that its commercial partner Everest Medicines received approval from the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China. The approval for Nefecon is for the treatment of primary immunoglobulin A nephropathy, or IgAN, in adults at risk of disease progression. Macau is the first region in Everest territories that received Nefecon approval. The NDA for Nefecon in mainland China is under Priority Review and Nefecon was the first non-oncology medicine to receive Breakthrough Therapy Designation in China. Nefecon has been available for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary through an early-access program since April.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CALT:
- Omeros’ failure alleviates competition for Calliditas, says H.C. Wainwright
- Calliditas Therapeutics announces COMP opinion on setanaxib
- Calliditas Therapeutics presents Phase 3 NefIgArd study data
- Calliditas Therapeutics partner submits request to MHRA to convert Kinpeygo CMA
- Calliditas Therapeutics presents data from the NefIgArd Phase 3 trial
